NASDAQ:XERS Xeris Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.40 -0.11 (-6.95%) (As of 06/29/2022 11:25 AM ET) Add Compare Share Today's Range$1.40▼$1.5250-Day Range$1.51▼$2.4652-Week Range$1.25▼$4.59Volume33,330 shsAverage Volume2.08 million shsMarket Capitalization$93.43 millionP/E RatioN/ADividend YieldN/APrice Target$6.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Stock Forecast (MarketRank)Overall MarketRank™2.06 out of 5 starsMedical Sector535th out of 1,433 stocksPharmaceutical Preparations Industry230th out of 685 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.13, Xeris Biopharma has a forecasted upside of 305.6% from its current price of $1.51.Amount of Analyst CoverageXeris Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesXeris Biopharma has received 130 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXeris Biopharma has received 61 “underperform” votes. (Add your “underperform” vote.)Community SentimentXeris Biopharma has received 68.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Xeris Biopharma and other stocks. Vote “Outperform” if you believe XERS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $140,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.01% of the stock of Xeris Biopharma is held by insiders.Percentage Held by InstitutionsOnly 18.72% of the stock of Xeris Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.83) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xeris Biopharma (NASDAQ:XERS)Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Read More XERS Stock News HeadlinesJune 15, 2022 | ca.proactiveinvestors.comXeris Biopharma addressing unique needs with 3 products in the market and a strong pipelineJune 9, 2022 | finance.yahoo.comAre Institutions Heavily Invested In Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares?May 27, 2022 | finance.yahoo.comBillionaire Israel Englander Pulls the Trigger on These 2 ‘Strong Buy’ Penny StocksMay 16, 2022 | seekingalpha.comXeris Biopharma spikes as CEO buys company sharesMay 13, 2022 | finance.yahoo.comXeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14May 11, 2022 | seekingalpha.comXeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | finance.yahoo.comXeris Biopharma Reports First Quarter Financial Results and Upcoming EventsMay 4, 2022 | finance.yahoo.comXeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022April 29, 2022 | nasdaq.comXeris Biopharma Holdings, Inc. Common Stock (XERS)April 28, 2022 | benzinga.comCraig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5April 28, 2022 | benzinga.comXeris Biopharma Shares Spike Higher; Hearing Craig-Hallum Initiates Coverage On The Stock With Buy Rating And $6.50 Price TargetMarch 23, 2022 | finance.yahoo.com10 Stocks I'm Watching in 2022: An UpdateMarch 16, 2022 | finance.yahoo.comXeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And AboveSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees294Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.13 High Stock Price Forecast$6.50 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+335.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-122.72 million Net Margins-217.81% Pretax Margin-218.45% Return on Equity-258.57% Return on Assets-58.47% Debt Debt-to-Equity Ratio1.43 Current Ratio2.67 Quick Ratio2.42 Sales & Book Value Annual Sales$49.59 million Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book0.98Miscellaneous Outstanding Shares66,497,000Free Float63,830,000Market Cap$93.43 million OptionableNot Optionable BetaN/A Xeris Biopharma Frequently Asked Questions Should I buy or sell Xeris Biopharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xeris Biopharma stock. View analyst ratings for Xeris Biopharma or view top-rated stocks. What is Xeris Biopharma's stock price forecast for 2022? 4 brokerages have issued twelve-month target prices for Xeris Biopharma's shares. Their XERS stock forecasts range from $6.00 to $6.50. On average, they predict Xeris Biopharma's share price to reach $6.13 in the next year. This suggests a possible upside of 335.9% from the stock's current price. View analysts' price targets for Xeris Biopharma or view top-rated stocks among Wall Street analysts. How has Xeris Biopharma's stock price performed in 2022? Xeris Biopharma's stock was trading at $2.93 at the beginning of 2022. Since then, XERS shares have decreased by 52.0% and is now trading at $1.4050. View the best growth stocks for 2022 here. When is Xeris Biopharma's next earnings date? Xeris Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Xeris Biopharma. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The business earned $22.07 million during the quarter, compared to the consensus estimate of $22.92 million. Xeris Biopharma had a negative net margin of 217.81% and a negative trailing twelve-month return on equity of 258.57%. View Xeris Biopharma's earnings history. Who are Xeris Biopharma's key executives? Xeris Biopharma's management team includes the following people: Mr. Paul R. Edick, Chairman & CEO (Age 66, Pay $1.27M) (LinkedIn Profile)Mr. John P. Shannon, Pres & COO (Age 60, Pay $966.64k)Ms. Beth P. Hecht J.D., Chief Legal Officer & Corp. Sec. (Age 58, Pay $662.99k)Dr. Steven J. Prestrelski MBA, Ph.D., Co-Founder & Chief Scientific Officer (Age 58)Mr. Steven M. Pieper, Chief Financial Officer (Age 45)Ms. Allison Wey, Sr. VP of Investor Relations & Corp. CommunicationsDr. Kenneth E. Johnson Pharm. D., Pharm.D., Sr. VP of Global Devel. & Medical Affairs (Age 59)Mr. Kevin McCulloch, Sr. VP of Global Operations & Bus. Devel. Who are some of Xeris Biopharma's key competitors? Some companies that are related to Xeris Biopharma include Aerovate Therapeutics (AVTE), Albireo Pharma (ALBO), Generation Bio (GBIO), BioXcel Therapeutics (BTAI), Karyopharm Therapeutics (KPTI), Vera Therapeutics (VERA), Khosla Ventures Acquisition (KVSA), Affimed (AFMD), Silence Therapeutics (SLN), Gracell Biotechnologies (GRCL), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), PyroGenesis Canada (PYR), Lexicon Pharmaceuticals (LXRX) and ALX Oncology (ALXO). View all of XERS's competitors. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI). When did Xeris Biopharma IPO? (XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. What is Xeris Biopharma's stock symbol? Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS." Who are Xeris Biopharma's major shareholders? Xeris Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.83%), BlackRock Inc. (3.00%), Goldman Sachs Group Inc. (1.09%), Renaissance Technologies LLC (1.04%), Granahan Investment Management LLC (0.61%) and State Street Corp (0.58%). Company insiders that own Xeris Biopharma stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski. View institutional ownership trends for Xeris Biopharma. Which major investors are selling Xeris Biopharma stock? XERS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deltec Asset Management LLC, Simplex Trading LLC, Granahan Investment Management LLC, Brown Advisory Inc., Commonwealth Equity Services LLC, Dimensional Fund Advisors LP, and Qube Research & Technologies Ltd. View insider buying and selling activity for Xeris Biopharma or view top insider-selling stocks. Which major investors are buying Xeris Biopharma stock? XERS stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Citigroup Inc., BlackRock Inc., Yakira Capital Management Inc., Vanguard Group Inc., Virtu Financial LLC, UBS Group AG, and Sciencast Management LP. View insider buying and selling activity for Xeris Biopharma or or view top insider-buying stocks. How do I buy shares of Xeris Biopharma? Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xeris Biopharma's stock price today? One share of XERS stock can currently be purchased for approximately $1.41. How much money does Xeris Biopharma make? Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $93.43 million and generates $49.59 million in revenue each year. The company earns $-122.72 million in net income (profit) each year or ($1.47) on an earnings per share basis. How many employees does Xeris Biopharma have? Xeris Biopharma employs 294 workers across the globe. How can I contact Xeris Biopharma? Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for Xeris Biopharma is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at [email protected]. This page (NASDAQ:XERS) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here